Arsanis, Inc. Announces Formation of Scientific Advisory Board

VIENNA--(BUSINESS WIRE)-- Arsanis, Inc., a biotechnology company dedicated to the development of anti-infective monoclonal antibodies, today announced the establishment of its Scientific Advisory Board to include six internationally recognized opinion leaders in the areas of infectious diseases and monoclonal antibody engineering.

“Arsanis is discovering anti-bacterial monoclonal antibodies for several infectious diseases with the aim to select development candidates in the next 18-24 months,” said Dr. Eszter Nagy, Co-founder and Chief Scientific Officer. "This outstanding team of experts provides us with strong scientific support in the discovery phase and program prioritization, as well as clinical and translational expertise to plan relevant and feasible clinical proof of concept studies. We are extremely pleased to have recruited such an outstanding team of scientists and clinicians to the Arsanis SAB."

”Within a very short period of time, Eszter pulled together an exceptional group of internationally recognized advisors. In my experience, the quality of the people you attract to a given problem correlates with the strength of your strategy to solving that problem. Arsanis is targeting several very relevant pathogens in the infectious disease area and the composition of its Scientific Advisory Board reflects that,” said Tillman Gerngross, Ph.D., Co-founder and President.

Scientific Advisory Board Members:

Rick Malley, M.D.

Dr. Malley is Kenneth McIntosh Chair in Pediatric Infectious Diseases at Children’s Hospital Boston and an Associate Professor of Pediatrics at Harvard Medical School. Besides being an active pediatric infectious disease clinician, his research laboratory focuses on pneumococcal pathogenesis and disease prevention with emphasis on correlates of protection and novel immune approaches based on vaccination. Dr. Malley authored and co-authored 80 scientific publications in the field of infectious diseases.

Robert C. Moellering, Jr., M.D.

Dr. Moellering is Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School, past Physician-in-Chief at several leading hospitals in Boston and past President and CEO of Harvard Medical Faculty Physicians at BIDMC. Dr. Moellering is one of the most respected infectious disease experts worldwide with 35 years of research, focusing on the mechanism of action and mechanisms of resistance to antimicrobial agents and reported in over 400 publications in international scientific journals. His achievements have earned Dr. Moellering honorary doctorates and countless awards.

Steven M. Opal, M.D.

Dr. Opal is Professor of Medicine in the Infectious Disease Division at The Warren Alpert Medical School of Brown University and Chief of Infectious Disease Division at Memorial Hospital of Rhode Island. Dr. Opal’s pivotal contribution to the infectious disease field is multi-fold including research on the patho-mechanism of septic shock, host-pathogen interaction in systemic infection and antibiotic resistance as well as clinical trial design, implementation and analysis of data from Phase I to Phase III studies. He is the editor of several academic research journals and textbooks and the chair of the International Sepsis Forum.

Claire Poyart, M.D., Ph.D.

Dr. Poyart is Professor of Medical Microbiology, University Paris Descartes, and Head of the Laboratory of Bacteriology of Cochin Hospital Head of the National Reference Centre for Streptococci in France. As a clinical microbiologist, her clinical research focuses on the epidemiological characterization of Group B Streptococcus, the development of diagnostic tools for the detection and the identification of Gram-positive bacteria. Her basic research is directed towards characterizing streptococcal virulence, and resulted in major contribution to the molecular understanding of the Group B Streptococcus disease mechanism. Dr. Poyart authored and co-authored 100 scientific publications in the field of clinical microbiology and infectious diseases.

Franz-Josef Schmitz, M.D.

Dr. Schmitz is the Medical Director of the Clinics and Director at the Institute for Laboratory Medicine, Microbiology, Hygiene, Environmental Medicine and Transfusion Medicine at the Mühlenkreis and Professor in Medical Microbiology at the University Clinic in Düsseldorf, Germany. His research interests are epidemiology and detection of antibiotic resistant bacterial pathogens, with special focus on Staphylococcal and multi-drug resistant Gram-negative infections. His work is published in over 200 scientific papers and he has authored several reviews and books on antibiotic resistance.

K. Dane Wittrup, Ph.D.

Dr. Wittrup is C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at Massachusetts Institute of Technology, the Associate Director of the Koch Institute for Integrative Cancer Research, co-founder and member of the Office of the Chief Scientific Officer at Adimab and co-founder of BioDisplay Technologies (acquired by Abbott Laboratories in 2001). Dr. Wittrup is a pioneer in protein engineering and tumor targeting methodologies. One of his key contributions is the establishment of the yeast surface display technology that also serves as a platform for monoclonal antibody discovery. Dr. Wittrup’s achievements are reflected by numerous patents and highly cited publications in prestigious research journals.

About Arsanis, Inc.

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated with high mortality in spite of low rates of antibiotic resistance. Using first-in-class monoclonal antibody discovery technologies that support the selection of highly potent antibodies with unique qualities, we are building a broad portfolio of infectious disease targets. The most successful pre-clinical programs will be advanced into clinical proof-of-relevance studies.

Arsanis is a Delaware Corporation with primary operations in Vienna, Austria and was founded in the fall of 2010 by Dr. Eszter Nagy (former SVP of Research at Intercell, AG), Dr. Tillman Gerngross (Co-founder and CEO of Adimab, and Co-founder and CSO of GlycoFi, Inc., a wholly owned subsidiary of Merck & Co. since 2006) and Errik Anderson (Co-founder and COO of Adimab) who bring together expertise in monoclonal antibody discovery, infectious disease biology and commercializing innovation.

For more information, please visit www.arsanis.com.



CONTACT:

Arsanis, Inc
Barbara Grell, +43 (676) 898543700
Senior Manager, Public Relations
[email protected]

KEYWORDS:   Austria  Europe

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases

MEDIA:

Suggested Articles

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.